FBLG
FibroBiologics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Consensus Rating "Strong Buy"
Significant Net Income Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FBLG
Fibrobiologics, Inc.
An early-stage cell therapy company working on innovative therapies to treat chronic diseases
455 E. Medical Center Blvd., Suite 300, Houston, Texas 77598
--
FibroBiologics, Inc., was originally incorporated as a limited liability company under the laws of Texas on April 8, 2021, and then transformed into a Delaware corporation on December 14, 2021. The Company is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients with chronic diseases with severe unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing and certain cancers, as well as potential life-prolonging applications including thymus and spleen convulsion reversal.
Company Financials
EPS
FBLG has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.12, missing expectations. The chart below visualizes how FBLG has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
